Clinical trial
A Lifestyle and Combination Medication Therapy Diabetes Prevention Study
NCT00116922 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Other · Completed
Key facts
| NCT number | NCT00116922 |
|---|---|
| Title | A Lifestyle and Combination Medication Therapy Diabetes Prevention Study |
| Official title | CAnadian Normoglycemia Outcomes Evaluation Study |
| Lead sponsor | Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Other |
| Collaborators | University of Western Ontario, Canada |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Impaired Glucose Tolerance, Diabetes |
| Intervention type | Drug |
| Interventions | Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID |
| Enrollment | 207 |
| Start date | Jun 1, 2004 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Jul 1, 2005 |
| Last update posted | May 24, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: